Shanghai OPM Biosciences Hits Day Low of CNY 40.50 Amid Price Pressure

Shanghai OPM Biosciences Co. experienced significant activity on June 2, 2026, with the stock declining by 8.34% and reaching an intraday low of CNY 40.50. This performance stands in contrast to the China Shanghai Composite, which saw a modest gain of 0.43% on the same day. Over the past week, Shanghai OPM has faced a decline of 7.7%, while its performance over the last month shows a more pronounced drop of 17.97%. Year-to-date, the stock has decreased by 15.9%, significantly underperforming the broader market, which has gained 2.68% during the same period. Despite a recent positive turnaround in March 2025, following seven consecutive quarters of negative results, the company has struggled with long-term growth metrics. Net sales have shown a modest annual growth rate of 6.53%, while operating profit has decreased by 43.06% over the last five years. The company's market capitalization stands at CNY 5,251 million, and it currently holds a price-to-earnings ratio of 146.00, indicating a challenging valuation landscape within the pharmaceuticals and biotechnology sector.